Loading
A phase 3 trial of CAIX PET in Clear cell renal cell carcinoma, run by Telix Pharmaceuticals (Innovations) Pty Limited, completed.
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study is a phase 3 interventional study registered as NCT03849118 by Telix Pharmaceuticals (Innovations) Pty Limited, with 300 participants recorded, started 2019-08-15 and reaching its primary completion in 2022-10-20. Interventions recorded: 89Zr-girentuximab. Conditions recorded: Clear Cell Renal Cell Carcinoma.
Linked to the technology CAIX PET because the registry names it ("89zr girentuximab") among its interventions and Clear cell renal cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CAIX PET (89Zr-girentuximab), Clear cell renal cell carcinoma and the tag pipeline.
Shares Telix Pharmaceuticals and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares Telix Pharmaceuticals and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares CAIX PET (89Zr-girentuximab), Telix Pharmaceuticals, Clear cell renal cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/